FDA Guidance Sets Lantern Pharma Inc. (NASDAQ: LTRN) On A Path Toward Realizing Its Clinical Trial Plans For Rare Pediatric Cancer Therapy

(MENAFN- Investor Brand Network)

• Texas-based clinical-stage biotechnology company Lantern Pharma Inc. is developing a number of clinical trials, using its proprietary drug candidates and computational biology and machine learning platform, to target conditions with unmet medical needs
• A recent Type C meeting with the U.S. Food and Drug Administration provided the company with guidance in working through the regulatory pathway and designing the trial for its investigational therapy LP-184/STAR-001, which will seek a means of battling pediatric brain cancers
• Lantern Pharma is also using drug candidates in trials to combat glioblastoma (“GBM”), triple-negative breast cancer, non-small cell lung cancer in non-smokers, non-Hodgkin's lymphoma, and other tumors
• Lantern's meeting with the FDA will help it amend its investigational new drug (“IND”) submission for the potential pediatric central nervous system cancer therapy LP-184/STAR-001 and a planned trial launch in Q1 of 2026
• Two of the company's current trials achieved a complete response in patients during the past quarter

Clinical-stage cancer technology company Lantern Pharma (NASDAQ: LTRN) is preparing for the launch of a trial targeting a rare pediatric disease, planned for Q1 2026, in the wake of the company's optimistic meeting with the U.S. Food and Drug Administration (“FDA”) to receive critical guidance on the company's trial design and the FDA's regulatory pathway.

Lantern Pharma is developing its clinical trial with the hope of demonstrating the efficacy of its investigational therapy LP-184/STAR-001 in combatting central nervous system (“CNS”) cancers, including Atypical Teratoid Rhabdoid Tumor (“ATRT”). The LP-184/STAR-001 therapy is designed to work...

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company's newsroom at

About AINewsWire

AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today's market, AINW brings its clients unparalleled recognition and brand awareness.

AINW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from AINewsWire, text“AI” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: imer, Angeles, CA

310.299.1717 Office
href="/cdn-cgi/l/email-protection#c287a6abb6adb082838b8ca7b5b195abb0a7eca1adaf" target="_blank" rel="noreferrer noopener">[email protected]

AINewsWire is powered by IBN

MENAFN30092025000224011066ID1110133586